REGENERON PHARMACEUTICALS, INC. executive McCourt Marion sold 2,346 shares across two transactions at prices ranging from $850 to $857.39 per share. The transactions left Marion with 12,003 shares, giving investors the disclosed post-sale ownership figure for the EVP Commercial.
Key Highlights
- McCourt Marion retained 12,003 shares after the transactions.
- The sales took place between Sep. 2 and Sep. 3, 2026.
- The transactions covered two sales of Regeneron shares.
REGENERON PHARMACEUTICALS, INC. (NASDAQ: REGN) executive McCourt Marion sold 2,346 shares at prices ranging from $850 to $857.39 per share. The EVP Commercial completed the sales in two transactions spanning Sep. 2 and Sep. 3, 2026.
Two Transactions Cover 2,346 Shares
The transactions were sales of Regeneron shares and carried transaction code S. The prices ranged from $850 to $857.39 per share. Marion’s combined sale amounted to 2,346 shares. McCourt Marion held 12,003 shares after completing the transactions.
Post-Sale Ownership Stands at 12,003 Shares
The disclosed remaining position was 12,003 shares following the sales. That figure represents Marion’s ownership after the two transactions. The filing identifies Marion as EVP Commercial.
FAQs
Q: How many Regeneron shares did McCourt Marion sell?
A: McCourt Marion sold 2,346 Regeneron shares across two transactions. The sales occurred at prices ranging from $850 to $857.39 per share.
Q: What happened to REGN executive share ownership after the sale?
A: After the two reported sales, McCourt Marion owned 12,003 Regeneron Pharmaceuticals shares. The filing identifies Marion as the company’s EVP Commercial.
Q: When did the Regeneron stock transactions occur?
A: The Regeneron stock sales took place between Sep. 2 and Sep. 3, 2026. The transactions were recorded as sales of shares.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.